Evidence map›Paper›PMID 38012682›Full record

ArticleClinical epigenetics2023

Long-term decitabine/retinoic acid maintenance treatment in an elderly sAML patient with high-risk genetics.

Nora Rebeka Javorniczky, Olga Grishina, Inga Hund, Milena Pantic, Dietmar Pfeifer, Claudia Schmoor, Johanna Thomas, Justus Duyster, Heiko Becker, Michael Lübbert

Registry-linked trialOpen access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical epigenetics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00867672 (Prospective Randomized Multicenter Phase II Trial of Low-dose Decitabine), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00867672 phase2completednot on this map

Prospective Randomized Multicenter Phase II Trial of Low-dose Decitabine (DAC) Administered Alone or in Combination With the Histone Deacetylase Inhibitor Valproic Acid (VPA) and All-trans Retinoic Acid (ATRA) in Patients > 60 Years With Acute Myeloid Leukemia Who Are Ineligible for Induction Chemotherapy

TypeinterventionalSponsorUniversity Hospital FreiburgRan2011 to 2016Enrolled204ConditionsAcute Myeloid LeukemiaArmsDecitabine, VPA, ATRA
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Nora Rebeka JavorniczkyDepartment of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Hugstetterstr. 55., 79106, Freiburg, Germany.
Olga GrishinaClinical Trials Unit, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Inga HundDepartment of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Hugstetterstr. 55., 79106, Freiburg, Germany.
Milena PanticDepartment of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Hugstetterstr. 55., 79106, Freiburg, Germany.
Dietmar PfeiferDepartment of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Hugstetterstr. 55., 79106, Freiburg, Germany.
Claudia SchmoorClinical Trials Unit, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Johanna ThomasDepartment of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Hugstetterstr. 55., 79106, Freiburg, Germany.
Justus DuysterDepartment of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Hugstetterstr. 55., 79106, Freiburg, Germany.
Heiko BeckerDepartment of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Hugstetterstr. 55., 79106, Freiburg, Germany.
Michael LübbertDepartment of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Hugstetterstr. 55., 79106, Freiburg, Germany. michael.luebbert@uniklinik-freiburg.de.
University Medical Center Freiburg · DEUniversity of Freiburg · DEGerman Cancer Research Center · DE

Funding

Deutsche Forschungsgemeinschaft 192904750Deutsche Forschungsgemeinschaft FOR2674 A05German Federal Ministry of Education and Research (BMBF, Clinical Trials Program 01KG0913
6 · The paper itself

Abstract

Elderly patients with AML ineligible for induction have a dismal prognosis; hence disease stabilization is a primary treatment goal. This case of a 75-year-old patient with secondary AML receiving the combination of decitabine and ATRA (within the DECIDER trial, NCT00867672) demonstrates an above-average survival. The therapy administered over 52 cycles led to complete molecular and hematological remission and resulted in 5.3 years overall survival. Clonal evolution of the leukemic clone could be demonstrated using DNA sequencing methods. According to the literature, this case constitutes the longest continued HMA exposure in an elderly AML patient ineligible for standard chemotherapy.

Indexed as

Leukemia, Myeloid, AcuteTretinoinAgedAntineoplastic Combined Chemotherapy ProtocolsDecitabineDNA MethylationHumansPrognosisTreatment OutcomeDecitabineTretinoin

Identifiers

PMID38012682
PMCPMC10683313
OpenAlexW4389068518

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.